Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Antibacterial Activity of Padikara Parpam against ESBL Producing Escherichia coli and Klebsiella pneumoniae

View through CrossRef
Aims: To evaluate the antibacterial activity of Padikara Parpam against Extended-Spectrum Beta-Lactamase (ESBL) producing Escherichia Coli and Klebsiella Pneumoniae using agar well diffusion method. To identify ESBL producing bacteria by phenotypic confirmatory test using disk diffusion method. Study Design: Analysis of Antibacterial activity of Padikara Parpam using agar well diffusion method. Place and Duration of Study: Central Research Laboratory, Meenakshi Academy of higher Education and Research, Chennai, between June 2021 and November 2021. Methodology: Clinical isolates of ESBL were isolated by subculture into MacConkey agar and was identified by phenotypic confirmatory test. Padikara parpam's antibacterial activity was evaluated using the Agar well diffusion method at different concentrations of 0.5 %, 1 %, 1.5 %, and 2 % drugs. 30 µg Cefotaxime and 30 µg amoxicillin-clavulanic acid disk were used as controls to standardize the antibacterial activity test and to identify the ESBL by phenotypic confirmatory test. Results: In this study, Padikara parpam at various doses of 0.5 %, 1 %, 1.5 %, and 2 %, revealed significant antibacterial efficacy against ESBL producing bacteria. Padikara parpam was more active against ESBL Escherichia coli than ESBL Klebsiella pneumoniae. As a result, it may be recommended as an antibacterial agent against ESBL. Conclusion: Our findings suggest that Siddha Herbo mineral formulations of padikara parpam hold phenomenal antimicrobial activity against ESBL producing bacteria. Based on our findings, the drug may be prescribed successfully for urinary tract infections, which is caused by ESBL producing bacteria.
Title: Antibacterial Activity of Padikara Parpam against ESBL Producing Escherichia coli and Klebsiella pneumoniae
Description:
Aims: To evaluate the antibacterial activity of Padikara Parpam against Extended-Spectrum Beta-Lactamase (ESBL) producing Escherichia Coli and Klebsiella Pneumoniae using agar well diffusion method.
To identify ESBL producing bacteria by phenotypic confirmatory test using disk diffusion method.
Study Design: Analysis of Antibacterial activity of Padikara Parpam using agar well diffusion method.
Place and Duration of Study: Central Research Laboratory, Meenakshi Academy of higher Education and Research, Chennai, between June 2021 and November 2021.
Methodology: Clinical isolates of ESBL were isolated by subculture into MacConkey agar and was identified by phenotypic confirmatory test.
Padikara parpam's antibacterial activity was evaluated using the Agar well diffusion method at different concentrations of 0.
5 %, 1 %, 1.
5 %, and 2 % drugs.
30 µg Cefotaxime and 30 µg amoxicillin-clavulanic acid disk were used as controls to standardize the antibacterial activity test and to identify the ESBL by phenotypic confirmatory test.
Results: In this study, Padikara parpam at various doses of 0.
5 %, 1 %, 1.
5 %, and 2 %, revealed significant antibacterial efficacy against ESBL producing bacteria.
Padikara parpam was more active against ESBL Escherichia coli than ESBL Klebsiella pneumoniae.
As a result, it may be recommended as an antibacterial agent against ESBL.
Conclusion: Our findings suggest that Siddha Herbo mineral formulations of padikara parpam hold phenomenal antimicrobial activity against ESBL producing bacteria.
Based on our findings, the drug may be prescribed successfully for urinary tract infections, which is caused by ESBL producing bacteria.

Related Results

Phenotypic and Molecular Characterization of the blaTEM Gene in Extended-Spectrum Beta-Lactamase-Producing Klebsiella pneumoniae
Phenotypic and Molecular Characterization of the blaTEM Gene in Extended-Spectrum Beta-Lactamase-Producing Klebsiella pneumoniae
Abstract Introduction There has been a notable rise in antibiotic resistance among enterobacteria. This issue is primarily attributed to the emergence of extended-spectrum beta-lac...
Evolution of Antimicrobial Resistance in Community vs. Hospital-Acquired Infections
Evolution of Antimicrobial Resistance in Community vs. Hospital-Acquired Infections
Abstract Introduction Hospitals are high-risk environments for infections. Despite the global recognition of these pathogens, few studies compare microorganisms from community-acqu...
Activity of Mecillinam and Clavulanic Acid on ESBL Producing and Non- ESBL Producing Escherichia Coli Isolated From UTI Cases
Activity of Mecillinam and Clavulanic Acid on ESBL Producing and Non- ESBL Producing Escherichia Coli Isolated From UTI Cases
Mecillinam is one of the very few oral antibacterial agents used against extended spectrum ?- lactamase (ESBL) producing Escherichia coli (E. coli) causing urinary tract infection ...

Back to Top